Научно-Исследовательский Институт Проблем Биологической Безопасности

(Русский) ПРЕМЬЕР-МИНИСТР РЕСПУБЛИКИ КАЗАХСТАН МАМИН А.У. ПОСЕТИЛ РГП «НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ПРОБЛЕМ БИОЛОГИЧЕСКОЙ БЕЗОПАСНОСТИ» КОМИТЕТА НАУКИ МИНИСТЕРСТВА ОБРАЗОВАНИЯ И НАУКИ РЕСПУБЛИКИ КАЗАХСТАН И ОФИЦИАЛЬНО ДАЛ СТАРТ СТРОИТЕЛЬСТВУ ПЕРВОГО В КАЗАХСТАНЕ GMP-ЗАВОДА ПО ВЫПУСКУ ИММУНОБИОЛОГИЧЕСКИХ ПРЕПАРАТОВ

Sorry, this entry is only available in Russian.

CONGRATULATION OF THE MINISTER OF EDUCATION AND SCIENCE OF THE REPUBLIC OF KAZAKHSTAN OF AYMAGAMBETOV ASKHAT KANATOVICH OF THE STAFF OF THE RESEARCH INSTITUTE FOR BIOLOGICAL SAFETY PROBLEMS OF SC MES RK

The Minister of Education and Science of the Republic of Kazakhstan Aymagambetov Askhat Kanatovich send a congratulatory letter to the scientists of the Research Institute for Biological Safety Problems of SC MES RK about the development of the inactivated vaccine against COVID-19 coronavirus infection and its registration on base of the World Health Organization. The Minister of Education and Science of the Republic of Kazakhstan Aymagambetov A.K. emphasized that this is a significant contribution of Kazakhstani science to ensuring the biological safety of domestic scientists, as well as evidence of the country’s strong scientific potential. He noted that the staff of the Research Institute of Biological Safety Problems of SC MES RK has once again shown its leading role in the development of new types of vaccines against dangerous and especially dangerous diseases and wished the staff good health, prosperity and new discoveries.

Below is a link to the WHO landscape document on registered vaccine candidates COVID-19 (the third position of the second page): https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines

WORKING VISIT OF AKIM OF THE ZHAMBYL REGION SAPARBAYEV BERDIBEK MASHBEKOVICH TO THE RESEARCH INSTITUTE FOR BIOLOGICAL SAFETY PROBLEMS OF THE SCIENCE COMMITTEE OF THE MINISTRY OF EDUCATION AND SCIENCE OF THE REPUBLIC OF KAZAKHSTAN

05/14/2020 Akim of the Zhambyl region Saparbayev Berdibek Mashbekovich, accompanied by the deputy Akim of the Zhambyl region, the Akim of the Kordai region and representatives of the Akimat’s and mass media’s office of the Zhambyl region and Kordai district paid a working visit to “Research Institute for Biological Safety Problems” of SC MES RK (RIBSP SC MES RK).

RIBSP SC MES RK Director General Zakarya K.D. acquainted the guests with the history of development, activities and achievements of the Institute, as well as clearly demonstrated biological products produced by the Institute. During the conversation, questions were raised on improving the performance of the Institute: problems of the production of biological products, the construction of a biopharmaceutical plant for the production of immunobiological preparations (vaccines).

Then, Akim of the Zhambyl region B.M. Saparbayev, the administration of the Institute conducted a study tour in the scientific and industrial restricted zone of the Institute, with a brief information on the activities, areas of research and the achievements of scientific laboratories.

Also, the delegation visited the site where the construction of a biopharmaceutical plant is planned. Akim of the Zhambyl region B.M. Saparbayev issued a number commissions on the construction of the plant.

Further, Akim of the Zhambyl region Saparbayev Berdibek Mashbekovich met with the staff of the Institute. In his speech, he drew attention to the fact that the President of the Republic of Kazakhstan, Kassym-Zhomart Kemelevich Tokayev, earlier, on March 25, 2020, when visiting the scientific center, praised the work of biologists, noting the importance of own developments to enhance the competencies of Kazakhstani science and that the state should pay more attention to the activities of biological laboratories. The head of state said that given the need to ensure the biological safety of Kazakhstan and the ability of COVID-19 to adapt to various climatic conditions, scientists need to begin work on creating a domestic vaccine against coronavirus.

In continuation of Akim of Zhambyl region B. Saparbayev said that we all should strongly support the instructions of the Head of State, it is necessary to pay the greatest attention to issues on ensuring the biological safety of the country and create all the necessary conditions for conducting scientific and production activities in accordance with the requirements of international GMP standards.

DEVELOPMENT OF NEW VECTOR BRUCELLOSIS VACCINE FOR HUMANS

Brucellosis – is a zoonotic disease transmitted from sick animals to humans, characterized by multiple lesions of human organs and systems, and due to social danger brucellosis is included in the list of quarantine diseases. For the first time in 1886 by the English scientist Bruce was discovered this disease. In his honor they were named Brucella, and the disease caused by them – Brucellosis.

To date, 10 species of brucellosis agent are known, among which B. melitensis, B. abortus, B. suis and B. canis are risks to human health. And B. melitensis causes the most severe and acute form of brucellosis, and in 80-90 % of cases is responsible for the disease of people with this infection. In humans, brucellosis is mainly characterized by acute inflammatory processes as well as numerous symptoms of influenza like disease. Lack of adequate treatment can lead to death or disability of the patient. Most cases of human brucellosis is result of professional contact with bacteria.

Illustrative photo: from open sources

Brucella can penetrate the body through microscopic damage on the skin, mucosa of the conjunctiva of the eyes, digestive and respiratory tracts. Most often, a person is infected by eating unboiled milk, meat, untreated water, while cutting of beef, treating the skins of sick animals and inhaling dust containing microscopic wool or manure residues. It is not difficult to guess that the risk of falling ill is highest in villagers who work with livestock and animal produce.

Brucellosis affects people on all continents, but in some parts of the planet the possibility of infection is highest. Kazakhstan is one of the top 25 hyperendemic brucellosis states of the world, where about 1900 new cases of brucellosis in humans are detected annually. This situation is directly related to the high prevalence of brucellosis among small cattle and cattle.

Brucellosis is the most common infectious zoonotic disease among agricultural animals of Kazakhstan, annually, for the fight against which about 90 % of budget funds are appropriated to republican veterinary laboratories.

On the background of the critical epidemic situation on brucellosis, the task of protecting the health of the population from this infection is strategic importance for our country. It is known that the complete eradication of brucellosis among farm animals is known to be the best way to prevent this disease in humans.

Vaccination is known to be the most effective way to eradicate of brucellosis of farm animals. The problem is that there are currently no effective and safe vaccines against brucellosis of cattle, and therefore studies aimed at them manufacture are relevant and needed at the Research Institute for Biological Safety Problems (RIBSP).

For the first time, in the last 25 years, completely safe and effective vaccine against cattle brucellosis based on influenza viral vectors has been developed at RIBSP, which in its technical and consumer characteristics is significantly superior to commercial preparations. Moreover, the possibility of effective use of this vaccine has been experimentally confirmed for small cattle.

The results of the studies are published in the international rating journals and reported at the international conferences. At present, the vaccine is registered in the Ministry of Agriculture of the Republic of Kazakhstan and is in the stage of postregistration tests.

Currently, the technology for manufacturing of vector brucellosis vaccine for humans on the base of recombinant influenza virus expressing immunodominant brucellosis proteins: L7/L12 (ribosomal) and OMP-16 (membrane, surface), which meeting the requirements of the national and the international standards has been developed at RIBSP. Method of its application is worked out and safety and immunogenicity of vaccine on laboratory animals is studied. The developed vaccine can be recommended for further preclinical and clinical tests, with successful providing of commission tests on laboratory animals for safety and protectivity of vaccine.

In the future, licensing of new vector brucellosis vaccine for humans is expected nationally and internationally both in Kazakhstan and abroad.

This development is primarily developed for the specific prevention of brucellosis in humans (veterinarians, animal workers’ herd managers, slaughterhouse workers laboratory staff, villagers) in regions with high prevalence of infection among animals. In addition, a national mobilization stock of vaccine can be created for emergency situations, including in case of terrorist threat as a result of the commercialization adjusting.

For consultation, contact for RSE “Research Institute for Biological Safety Problems” SC MES RK by phone +7 (726-36) 7-22-28,

by e-mail: ribsp@biosafety.kz